News

Press ReleaseKing's College London spins out Korecyte Bio Ltd with investment and support from Cell and Gene Therapy Catapult to advance novel CAR-T platform for solid tumours
Filter:AllPress ReleaseCell TherapiesGene TherapiesDigital and AutomationSpin-outs, Start-ups, Sector investmentManufacturingRegulatory affairsSkills and Training
Year:All2026202520242023 →
Regulatory Round-up - September 2025Regulatory Round-up - September 2025R&D project spotlight: Deciphering rAAV production dynamics in HEK293 clones through multi-omics profilingR&D project spotlight: Deciphering rAAV production dynamics in HEK293 clones through multi-omics profilingCGT Catapult supporting VascVersa to develop pre-treatment test to ensure efficacy of cell therapy that regenerates blood vesselsCGT Catapult supporting VascVersa to develop pre-treatment test to ensure efficacy of cell therapy that regenerates blood vesselsThe case for collaboration: Why going it alone is no longer an option in advanced therapy developmentThe case for collaboration: Why going it alone is no longer an option in advanced therapy developmentRegulatory Round-up - August 2025Regulatory Round-up - August 2025R&D project spotlight: Developing a smart bioprocessing platform integrating real-time process monitoring and advanced process control for autologous cell therapyR&D project spotlight: Developing a smart bioprocessing platform integrating real-time process monitoring and advanced process control for autologous cell therapyRegulatory Round-up - July 2025Regulatory Round-up - July 2025MHRA introduces regulations that allow decentralised manufacturing of therapiesMHRA introduces regulations that allow decentralised manufacturing of therapiesCell and Gene Therapy Catapult appoints Dr Jim Faulkner as new ChairCell and Gene Therapy Catapult appoints Dr Jim Faulkner as new ChairCell and Gene Therapy Catapult appoints Dr Ed Samuel as Chief Operating OfficerCell and Gene Therapy Catapult appoints Dr Ed Samuel as Chief Operating OfficerSpliceor receives investment from the Cell and Gene Therapy Catapult as part of the Cross-Catapult Investment PilotSpliceor receives investment from the Cell and Gene Therapy Catapult as part of the Cross-Catapult Investment PilotCGT Catapult response to publication of the Life Sciences Sector PlanCGT Catapult response to publication of the Life Sciences Sector Plan